[CAS NO. 2070009-67-3] Paricalcitol-d6
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:
PRODUCTS SPECIFICATIONS [2070009-67-3]
Store
Catalog
HY-76585
Brand
MCE
CAS
2070009-67-3
DESCRIPTION [2070009-67-3]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 422.67 |
| Molecular Formula | C27H38D6O3 |
| SMILES | C[C@]([C@@H]([C@@H](/C=C/[C@@H](C(C([2H])([2H])[2H])(C([2H])([2H])[2H])O)C)C)CC1)(CCC/2)[C@@]1(C2=C\C=C3C[C@H](C[C@@H](C/3)O)O)[H] |
For research use only. We do not sell to patients.
Summary
Paricalcitol-d6 is the deuterium labeled Paricalcitol. Paricalcitol is a drug used for the prevention and treatment of secondary hyperparathyroidism (excessive secretion of parathyroid hormone) associated with chronic renal failure [1] .
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL ( 236.59 mM ; Need ultrasonic)
Preparing
Stock Solutions
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.3659 mL | 11.8296 mL | 23.6591 mL |
| 5 mM | 0.4732 mL | 2.3659 mL | 4.7318 mL |
| 10 mM | 0.2366 mL | 1.1830 mL | 2.3659 mL |
*
Please refer to the solubility information to select the appropriate solvent.
References
- [1] Martinez-Moreno JM, et al. In vascular smooth muscle cells paricalcitol prevents phosphate-induced Wnt/beta-catenin activation. Am J Physiol Renal Physiol. 2012 Aug 8.
- [2] Ari E, Kedrah AE, Alahdab Y, Bulut G, Eren Z, Baytekin O, Odabasi D. Antioxidant and renoprotective effects of paricalcitol on experimental contrast-induced nephropathy model. Br J Radiol. 2012 Aug;85(1016):1038-43.
- [3] Meems LM, Cannon MV, Mahmud H, Voors AA, van Gilst WH, Silljé HH, Ruifrok WP, de Boer RA. The vitamin D receptor activator paricalcitol prevents fibrosis and diastolic dysfunction in a murine model of pressure overload. J Steroid Biochem Mol Biol. 2012
- [4] Blanco-García R, et al. Microalbuminuria, another use for paricalcitol? Our experience in advanced chronic kidney disease. Nefrologia. 2012 May 14;32(3):401-2. doi: 10.3265/Nefrologia.pre2012.Feb.11378.
- [5] Piao SG, Song JC, Lim SW, Chung BH, Choi BS, Yang CW. Protective effect of paricalcitol on cyclosporine-induced renal injury in rats. Transplant Proc. 2012 Apr;44(3):642-5.
Powered by Arctom Copyright © 2026 Arctom. All rights
reserved.